Ipsen and Medicis submit US BLA for Reloxin

French drugmaker Ipsen and the USA's Medicis have submitted a Biologics License Application for their botulinum toxin type A product for esthetic applications, Reloxin, to the US Food and Drug Administration's Division of Dermatology and Dental Products. Medicis anticipates a response from the agency in approximately 10 months following its receipt of the submission. Current growth for this agent in its US cosmetic setting is estimated to be in excess of 20% over the prior year, in an esthetic market worth between $300.0 million to $400.0 million.